# Protagonist Therapeutics

Type: Company (PTGX)

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/protagonist-therapeutics
Canonical HTML page: https://getfinancebrief.com/entity/protagonist-therapeutics

## Timeline

- **2026-03-18**: Quarterly Earnings Release — Official financial results and conference calls scheduled for both companies.
- **2026-03-17**: Pre-Earnings Market Activity — Both OEZVY and PTGX see increased trading volume ahead of Wednesday reports.
- **2026-02-26**: Takeda Deal Restructuring — Protagonist opts out of profit-sharing for Rusfertide in exchange for $400M cash.
- **2026-02-25**: Institutional Exit Revealed — 13F filings reveal a $170 million divestment by a major institutional fund.
- **2026-01-20**: 120% Gain Milestone — PTGX stock reaches a 120% gain milestone from its 52-week low.
- **2025-11-01**: J&J Partnership Milestone — Johnson & Johnson advances JNJ-2113 into late-stage trials, validating oral peptide tech.
- **2025-06-15**: Phase 3 Data Release — Positive Phase 3 data for rusfertide in polycythemia vera triggers initial stock rally.

## Recent coverage (2 stories)

### Verbund and Protagonist Therapeutics Set for Key Mid-Week Earnings Reports
2026-03-17 07:34:46 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Austrian utility giant Verbund and biotech firm Protagonist Therapeutics are scheduled to release quarterly results this Wednesday. Investors will be scrutinizing Verbund's hydropower margins and Protagonist's cash position following its recent $400 million deal with Takeda.
Full story: https://getfinancebrief.com/story/verbund-protagonist-earnings-preview-march-2026

### Protagonist Stock Surges 120% as Major Fund Reveals $170 Million Exit
2026-02-25 21:49:49 · Sentiment: Neutral · Impact: 6/10 · Sources: 2

Protagonist Therapeutics shares have soared 120% following clinical and regulatory milestones, but a recent $170 million institutional exit is raising questions about the stock's near-term ceiling. The move highlights a growing divergence between retail momentum and institutional profit-taking in the biotech sector.
Full story: https://getfinancebrief.com/story/protagonist-therapeutics-stock-surge-institutional-exit

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.